SDREGN2810 + ipilimumab

SDREGN2810 + ipilimumab is a combination therapy consisting of two agents used in cancer immunotherapy. Ipilimumab is a monoclonal antibody that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), an immune checkpoint receptor on T cells. By blocking CTLA-4, ipilimumab enhances the immune system's ability to recognize and destroy cancer cells[2][6][7]. It is approved for use in several cancers, including melanoma, renal cell carcinoma, colorectal cancer (especially microsatellite instability-high or mismatch repair deficient types), hepatocellular carcinoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, and esophageal cancer[1][2][3][6]. SDREGN2810 appears to be a code name for an investigational drug; however, no detailed public information about its mechanism of action or developer could be found in the provided sources. The combination with ipilimumab suggests it may also function as an immunotherapy agent.

Brand names

Yervoy